{"slideshow_credits": null, "snippet": "The drug maker agreed to pay $688 million to settle two lawsuits that said it had harmed investors by delaying the release of unfavorable study results for a cholesterol drug.", "abstract": "Merck agrees to pay $688 million to settle two lawsuits claiming that it had harmed investors by delaying the release of unfavorable study results for its cholesterol drug Vytorin.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/15/business/merck-settles-investor-suits-over-cholesterol-drug.html", "lead_paragraph": "The drug maker agreed to pay $688 million to settle two lawsuits that said it had harmed investors by delaying the release of unfavorable study results for a cholesterol drug.", "headline": {"seo": "Merck Settles Investor Suits Over Cholesterol Drug", "main": "Merck Settles Suits Over Cholesterol Drug", "print_headline": "Merck Settles Suits Over Cholesterol Drug"}, "_id": "511d419c00315214fbb8b95c", "word_count": "757", "multimedia": [{"height": 126, "url": "images/2013/02/15/business/subMerck/subMerck-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/02/15/business/subMerck/subMerck-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 833, "url": "images/2013/02/15/business/subMerck/subMerck-articleLarge.jpg", "legacy": {"xlarge": "images/2013/02/15/business/subMerck/subMerck-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "833"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/02/15/business/subMerck/subMerck-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/02/15/business/subMerck/subMerck-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-02-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Merck & Company Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Vytorin (Drug)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Cholesterol", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Schering-Plough Corp", "name": "organizations", "is_major": "N", "rank": "4"}, {"value": "Suits and Litigation", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Decisions and Verdicts", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Zetia (Drug)", "name": "subject", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}